The University of Michigan Comprehensive Cancer Center and Tempus partner to bring MI-ONCOSEQ to patients and healthcare providers

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER and Tempus, a health-tech company focused on personalizing cancer care, and have partnered to bring MI-ONCOSEQ to patients and healthcare providers across the country who are seeking the high quality data and analyses necessary to personalize treatment for their patients. The MI-ONCOSEQ panel was developed at the University...

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login